Iran has launched three new radiopharmaceutical innovations and its National Nuclear Education Network in Tehran.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Austin, TX, April 28, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for ...

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression ...

We are initiating coverage of Radiopharm Theranostics Limited (NASDAQ:RADX) and assign a valuation of $12.50 per American Depository Receipt (ADR). This valuation is based on our estimates for ...

SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (RADX) (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June ...

Actinium-225, an alpha-emitting radiopharmaceutical, targets cancer cells precisely, sparing healthy tissue, and is being trialed for advanced breast cancer in the U.S. The phase 1b/2 trial involves ...